Creative Biolabs specializes in the synthesis of diabodies (db) for antibody production, focusing on high affinity and low immunogenicity for research and clinical applications. Their innovative techniques involve disulfide bonds and tandem gene linking to enhance the efficiency of heterodimerization, as well as the development of single chain diabodies and variants with increased valency. The company aims to deliver tailored db products for a wide range of antigens through collaboration with skilled scientists and global partners.

1. diabody
• With unchallenged experience in diabody (Db) synthesis, Creative
Biolabs has long been well-known in the field of antibody production.
We elaborately integrate our multiple platforms for providing
customer a desired Db with high affinity and low immunogenicity for
both academic and clinical purposes.

2. • Usually, Db is comprised of two chains expressed separately, each of which consists of a VH from
one antibody and a VL from another antibody. To improve the efficiency of the heterodimerization
process, disulfide bond or knobs-and-holes is introduced into the variant domains. In addition, by
tandem linking genes in each chain with internal linker, four VH and VL domains can be expressed
in tandem and folded as single chain diabody (scDb), which is also an effective strategy for
bispecific antibody producton. Furthermore, fusing recombinant variable domains to an Fc region
or CH3 domain (scDb-Fc and scDb-CH3) can not only help the chain-pairing process, but also
double the valency of the final product. Meanwhile, the increased size can also significantly
prolong the half-life of Db in serum.
• With its talented scientists and expert partners globally, Creative Biolabs is committed to
providing Db and all of its derivatives targeting almost any pair of antigens with high-affinity.